R&D Trends

Parker Institute, Bristol-Myers Squibb, Cancer Research Institute collaborate

Wednesday, March 29, 2017

The Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb and the Cancer Research Institute (CRI) have announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with Parker Institute and CRI scientists and researchers, soliciting clinical research proposals from their networks and coordinating multi-site collaboration clinical studies to pursue some of the most difficult questions in cancer research. It will provide scientists with an ecosystem of advanced translational tools, precision immunotherapy and cutting-edge bioanalytical expertise to maximize learning and ensure the generation of high quality data to inform future development.

[Read More]

AbbVie joins ORIEN Avatar Research Program

Wednesday, March 29, 2017

AbbVie, a global biopharmaceutical company, and M2Gen, a health informatics solutions company, announced that AbbVie has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials.

[Read More]

GlaxoSmithKline, Regeneron partner to generate genetic sequence data

Thursday, March 23, 2017

Regeneron Pharmaceuticals has announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.

[Read More]

Pierre Fabre, H-Immune partner to develop cancer immunotherapies

Tuesday, March 21, 2017

Pierre Fabre, a privately held pharmaceutical company in France, and H-Immune, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

[Read More]

X-Chem, Ono partner for drug discovery collaboration

Tuesday, March 21, 2017

X-Chem, a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, partnered with Ono Pharmaceutical. Under the terms of the agreement, X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple promising, high-impact oncology targets.

[Read More]

X-Chem, Astellas Pharma collaboration across multiple therapeutic areas

Monday, March 20, 2017

X-Chem, a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma. The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEXTM libraries containing over 120 billion compounds. This new partnership is X-Chem’s most expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas.

[Read More]